BioSpace News Archive

Fate Therapeutics, Inc. announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 40,000 shares of the Company’s common stock at an exercise price per share of $7.74, which was the closing price per share of the Company’s common stock as reported by NASDAQ on the grant effective date of March 1, 2024.

Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2023 and revenue outlook for 2024.

Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations.

Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023.

Mestag Therapeutics announced the acceptance of a late-breaking abstract titled “Conditionally active, therapeutic lymphotoxin beta receptor agonist bispecific antibodies for induction of tertiary lymphoid structures in the treatment of solid tumors” for presentation at the American Association for Cancer Research meeting taking place April 5-10, 2024 in San Diego, CA.

Orthofix Medical Inc. reported its financial results for the fourth quarter and year ended December 31, 2023, and issued guidance for the full year 2024.

Black Diamond Therapeutics, Inc., a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced an upcoming oral presentation at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Werewolf Therapeutics, Inc. announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Lyell Immunopharma, Inc. announced that three abstracts of new nonclinical data have been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 taking place in San Diego, CA, April 5-10.